- Home
- LXRX vs ANNX Comparison
LXRX vs ANNX Comparison
Compare LXRX & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXRX
- ANNX
- Stock Information
- Founded
- LXRX 1995
- ANNX 2011
- Country
- LXRX United States
- ANNX United States
- Employees
- LXRX N/A
- ANNX N/A
- Industry
- LXRX Biotechnology: Pharmaceutical Preparations
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- LXRX Health Care
- ANNX Health Care
- Exchange
- LXRX Nasdaq
- ANNX Nasdaq
- Market Cap
- LXRX 650.7M
- ANNX 668.8M
- IPO Year
- LXRX 2000
- ANNX 2020
- Fundamental
- Price
- LXRX $0.98
- ANNX $6.12
- Analyst Decision
- LXRX Buy
- ANNX Strong Buy
- Analyst Count
- LXRX 2
- ANNX 7
- Target Price
- LXRX $6.00
- ANNX $15.80
- AVG Volume (30 Days)
- LXRX 4.3M
- ANNX 1.2M
- Earning Date
- LXRX 11-12-2024
- ANNX 11-14-2024
- Dividend Yield
- LXRX N/A
- ANNX N/A
- EPS Growth
- LXRX N/A
- ANNX N/A
- EPS
- LXRX N/A
- ANNX N/A
- Revenue
- LXRX $5,229,000.00
- ANNX N/A
- Revenue This Year
- LXRX $1,212.46
- ANNX N/A
- Revenue Next Year
- LXRX $219.10
- ANNX N/A
- P/E Ratio
- LXRX N/A
- ANNX N/A
- Revenue Growth
- LXRX 886.60
- ANNX N/A
- 52 Week Low
- LXRX $0.97
- ANNX $2.27
- 52 Week High
- LXRX $3.73
- ANNX $8.40
- Technical
- Relative Strength Index (RSI)
- LXRX 25.78
- ANNX 30.04
- Support Level
- LXRX $1.01
- ANNX $6.85
- Resistance Level
- LXRX $1.35
- ANNX $7.63
- Average True Range (ATR)
- LXRX 0.12
- ANNX 0.32
- MACD
- LXRX -0.06
- ANNX -0.17
- Stochastic Oscillator
- LXRX 0.43
- ANNX 6.22
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.